Skip to main content
Fig. 11 | Cell Communication and Signaling

Fig. 11

From: The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma

Fig. 11

Erastin treatment inhibited tumorgenesis and development of HCC in vivo. a-c The original tumors (a), tumor volume (b) and tumor weight (c) under erastin treatment. d Histological changes of heart, liver, lung and kidneys in tumor-bearing and non-bearing mice under elastin treatment. e Weight change of mice under erastin treatment over time. f Pathological characteristics of tumor tissues and expression of Ki67 and N-cadherin in tumor tissues under erastin treatment. G Expression differences of ABCB6, FLVCR1, SLC7A11 and SLC48A1 between erastin-treated tumor tissues and vehicle-treated tumor tissues

Back to article page